Genmab A/ S stock (DK0010272202): Shares up 3.48% on employee warrant exercise

Genmab A/S announced a minor share capital increase after employee warrant exercises, adding 2,346 new shares. The stock rose 3.48% to $27.09 on May 12, 2026, amid ongoing biotech developments.

Genmab A/S, listed on Nasdaq as GMAB, reported a small share capital increase following employee warrant exercises, adding 2,346 new ordinary shares at prices between DKK 1,147.50 and DKK 1,362.50 per share, generating about DKK 3.0 million in proceeds, StockTitan as of May 2026. The total share capital now stands at DKK 62,353,067, with new shares entitled to dividends from subscription date. Separately, new shares will be admitted to trading on May 19, 2026, Nasdaq as of May 2026. The stock gained 3.48% to $27.09 on May 12, 2026, according to StockInvest as of May 12, 2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Genmab A/S
• Sector/industry: Biotechnology
• Headquarters/country: Denmark
• Core markets: Global, with US exposure via Nasdaq listing
• Key revenue drivers: Antibody therapeutics for cancer
• Home exchange/listing venue: Nasdaq Copenhagen (GMAB.CO), Nasdaq (GMAB)
• Trading currency: USD (Nasdaq), DKK (Copenhagen)

Genmab A/S: core business model

Genmab A/S is a Denmark-based biotechnology firm that develops antibody-based products and candidates primarily for cancer treatment and other diseases. The company focuses on innovative antibody therapeutics, partnering with global pharma players for commercialization. Its pipeline includes next-generation antibodies leveraging proprietary technologies like DuoBody and HexaBody.

Genmab generates revenue through royalties, milestones, and sales from approved products like Darzalex, developed in collaboration with Johnson & Johnson. The Nasdaq-listed shares (GMAB) provide US investors direct access to this European biotech leader, with market cap around €14.07 billion as reported by Simply Wall St as of May 2026.

Main revenue and product drivers for Genmab A/S

Key products include Darzalex (daratumumab), from which Genmab earns royalties, contributing significantly to revenue of €3.32 billion in recent fundamentals. Other drivers are epcoritamab (EPKINLY) and tivocemab, advancing in clinical trials for blood cancers and solid tumors. Milestone payments from partners like AbbVie and Pfizer bolster cash flow.

For US investors, Genmab's Nasdaq listing and exposure to the world's largest pharma market via US approvals and sales make it relevant, with products addressing high-demand oncology needs.

Industry trends and competitive position

The biotech sector sees rising demand for antibody-drug conjugates and bispecific antibodies, areas where Genmab excels. Competitors include Regeneron and Amgen, but Genmab's tech platforms differentiate it. Recent capital measures like warrant exercises support R&D funding amid volatile biotech funding environments.

Why Genmab A/S matters for US investors

With ADRs on Nasdaq, Genmab offers US retail investors exposure to innovative oncology biotech without currency risk on USD trades. Its partnerships with US giants like Johnson & Johnson tie performance to American market dynamics, including FDA approvals.

Conclusion

Genmab A/S continues advancing its antibody pipeline amid routine capital updates like recent warrant exercises and a 3.48% share price gain. The company's strong fundamentals and US listing position it in the competitive biotech space. Investors track upcoming listings and clinical milestones for further insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.